8-K: ABVC BioPharma and OncoX BioPharma Partner on Triple Negative Breast Cancer Therapy, Potential $13.75M Income and Royalties

ABVC BioPharma and OncoX BioPharma have entered into a licensing agreement to develop and commercialize a combination therapy for Triple Negative Breast Cancer, potentially generating $13.75 million in income and up to $12.5 million in royalties.

Summary

• ABVC BioPharma and its subsidiary BioLite, Inc. have partnered with OncoX BioPharma to develop a combination therapy for Triple Negative Breast Cancer (TNBC).
• The agreement grants OncoX exclusive rights to develop and commercialize ABVC's BLEX 404, a botanical drug extract from Maitake mushrooms, in 50% of the worldwide markets for 20 years.
• ABVC will receive an upfront payment of $6.25 million (or 1.25 million OncoX shares valued at $5 per share) within 30 days of the agreement, plus a $625,000 milestone payment after OncoX's next fundraising round.
• OncoX may make partial cash payments of at least $100,000 towards the licensing fees, which will be deducted from the second milestone payment.
• ABVC is also entitled to 5% royalties on net sales of the licensed product, up to a total of $12.5 million.
• The total potential income from the agreement is $13.75 million in licensing fees and up to $12.5 million in royalties.
• The agreement also includes technology sharing and intellectual property rights provisions.
• ABVC will be responsible for clinical development outside the licensed territory, while OncoX will handle development and commercialization within the territory.
• The global cancer therapeutics market is projected to reach $393.61 billion by 2032, with the TNBC market expected to reach $1.46 billion by 2030.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the potential financial benefits and the collaboration to address a significant unmet medical need. The partnership is a positive step for ABVC, but there are still risks associated with drug development and commercialization.

Positives

• The licensing agreement provides ABVC with a significant potential revenue stream through upfront payments, milestone payments, and royalties.
• The partnership with OncoX leverages both companies' expertise in drug development and oncology.
• The agreement targets a significant unmet medical need in Triple Negative Breast Cancer treatment.
• The 20-year licensing term provides long-term revenue potential.
• The agreement includes technology sharing, which could benefit both parties.
• The potential for $13.75 million in licensing fees and up to $12.5 million in royalties is a substantial financial opportunity for ABVC.
• The agreement covers 50% of the worldwide market, providing a large potential market for the licensed product.

Negatives

• The milestone payment of $625,000 is contingent on OncoX's next round of fundraising, which is not guaranteed.
• The royalty payments are dependent on the successful commercialization of the licensed product, which is uncertain.
• There is no guarantee that ABVC will receive the full $12.5 million in royalties.
• The agreement is for 50% of the worldwide market, meaning ABVC will not benefit from sales in the other 50% of the market.
• The manufacturing of the licensed product is subject to further negotiation.

Risks

• The success of the combination therapy is not guaranteed, and clinical trials may not be successful.
• Regulatory approvals for the licensed product are not guaranteed.
• OncoX may not be successful in commercializing the product.
• The market for TNBC treatments is competitive.
• The agreement is subject to various risks and uncertainties, including those related to manufacturing, financing, and regulatory approvals.
• The agreement is dependent on OncoX's ability to raise further capital.

Future Outlook

The companies aim to accelerate the development timeline and maximize the therapeutic potential of the combined approach through preclinical studies, clinical trials, and regulatory initiatives. The global cancer therapeutics market is expected to grow significantly, and the TNBC market is also expected to expand.

Management Comments

• Dr. Uttam Patil, ABVC's CEO, stated that the partnership addresses the urgent need for more effective treatments for TNBC.
• Dr. Patil also mentioned that ABVC and OncoX have joined forces to explore a novel therapeutic approach that holds promise for improving outcomes and quality of life for TNBC patients.
• Wen-Pin Yen, CEO of OncoX, expressed excitement about the collaboration and its potential to advance the field of oncology.

Industry Context

This announcement aligns with the broader industry trend of developing combination therapies to address complex diseases like cancer. The focus on TNBC reflects the unmet need for effective treatments in this aggressive form of breast cancer. The collaboration between a clinical-stage biopharma company and a private company highlights the importance of partnerships in drug development.

Comparison to Industry Standards

• The licensing agreement structure, with upfront payments, milestone payments, and royalties, is a common practice in the pharmaceutical industry.
• The 5% royalty rate is within the typical range for pharmaceutical licensing agreements, although it can vary based on the stage of development and market potential.
• The 20-year licensing term is standard for pharmaceutical products.
• Comparable companies in the oncology space often engage in similar licensing and collaboration agreements to advance their drug pipelines.
• For example, companies like Exelixis and Seattle Genetics have entered into licensing agreements for their oncology assets, with similar financial structures.
• The focus on a botanical drug extract is less common than traditional small molecule or biologic drugs, but there is a growing interest in natural products for therapeutic applications.

Stakeholder Impact

• Shareholders of ABVC may view this agreement positively due to the potential revenue and growth opportunities.
• Employees of both companies may be impacted by the collaboration and the development of the new therapy.
• Patients with Triple Negative Breast Cancer may benefit from the development of a new treatment option.
• Suppliers and partners of both companies may be impacted by the manufacturing and commercialization of the licensed product.

Next Steps

• OncoX will begin development and commercialization of BLEX 404 in the licensed territory.
• ABVC will continue clinical development of the licensed product outside the licensed territory.
• Both companies will collaborate on preclinical studies, clinical trials, and regulatory initiatives.
• Further study and analysis are to be performed for the feasibility from technical and financial perspective before the execution of related manufacturing agreement.

Key Dates

Keywords

Triple Negative Breast Cancer, TNBC, BLEX 404, Maitake Mushroom, OncoX BioPharma, ABVC BioPharma, Licensing Agreement, Combination Therapy, Royalties, Biopharmaceutical, Drug Development, Oncology